瑞戈非尼联合微波消融、肝动脉插管化疗栓塞术治疗原发性肝癌的效果  

The effect of regorafenib combined with microwave ablation and transcatheter arterial chemoembolization in the treatment of primary liver cancer

作　　者：陈枫 Chen Feng(Surgery Department of Tianjin Second People's Hospital,Tianjin 300192,China)

机构地区：[1]天津市第二人民医院外科,天津300192

出　　处：《临床普外科电子杂志》2024年第4期16-21,共6页Journal of General Surgery for Clinicians(Electronic Version)

摘　　要：目的探究瑞戈非尼联合微波消融、肝动脉插管化疗栓塞术(transcatheter arterial chemoembolization,TACE)治疗原发性肝癌的效果。方法选取天津市第二人民医院2023年10月至2024年4月收治的原发性肝癌患者74例,采用病历号信封抽签法分为观察组、对照组,每组各37例。对照组行微波消融联合TACE治疗,观察组行瑞戈非尼联合微波消融、TACE治疗,对比两组的近期疗效、肿瘤标志物、生物标志物、肝功能及不良反应情况。结果观察组患者的疾病控制率显著高于对照组,差异有显著性(P<0.05)。治疗后,观察组患者的细胞角蛋白19、甲胎蛋白、癌胚抗原水平,以及谷草转氨酶、谷丙转氨酶水平均显著低于对照组,脆性组氨酸三联体、P16蛋白及白蛋白水平均高于对照组,差异均有显著性(P<0.05)。观察组中9例患者出现不良反应,对照组中10例患者出现不良反应,两组患者的不良反应发生率无显著差异(P>0.05)。结论原发性肝癌行瑞戈非尼联合微波消融、TACE治疗,可提高近期疗效,改善肝功能损伤,且安全性较高。Objective To investigate the efficacy of regorafenib combined with microwave ablation and percutaneous transhepatic arterial chemoembolization(TACE)in the treatment of primary liver cancer.Method Seventy four patients with primary liver cancer admitted to the Tianjin Second People's Hospital from October 2023 to April 2024 were selected and divided into an observation group and a control group using the medical record number envelope drawing method,with 37 patients in each group.The control group received microwave ablation combined with TACE treatment,while the observation group received regorafenib combined with microwave ablation and TACE treatment.The short-term efficacy,tumor markers,biomarkers,liver function,and adverse reactions of the two groups were compared.Result The disease control rate of the observation group patients was significantly higher than that of the control group,and the difference was significant(P<0.05).After treatment,the levels of cytokeratin 19,alpha fetoprotein,carcinoembryonic antigen,as well as alanine aminotransferase and alanine aminotransferase in the observation group were significantly lower than those in the control group.The levels of fragile histidine triad,P16 protein,and albumin were higher than those in the control group,and the differences were significant(P<0.05).Nine patients in the observation group experienced adverse reactions,while ten patients in the control group experienced adverse reactions.There was no significant difference in the incidence of adverse reactions between the two groups of patients(P>0.05).Conclusion Primary liver cancer treated with regorafenib combined with microwave ablation and TACE can improve short-term efficacy,alleviate liver function damage,and with high safety.

关 键 词：瑞戈非尼 微波消融 肝动脉插管化疗栓塞 原发性肝癌 

分 类 号：R735.7[医药卫生—肿瘤]